leukemia
Researchers Report on Novel Pediatric AML Subtype Associated With Poor Outcomes at ASH Meeting
The analysis suggested that pediatric relapsed AML patients with UBTF tandem duplications had poorer outcomes than those without them.
Tibsovo, Azacitidine Combo Shows Improved Survival, Response in Newly Diagnosed IDH1-Mutant AML
Researchers at the ASH annual meeting suggested that Tibsovo-azacitidine could be a better option than Venclexta-azacitidine for chemo ineligible IDH1-mutant AML patients.
Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests
The company is planning to develop circulating tumor cell assays for prostate cancer and acute myeloid leukemia and to launch them in the US.
Kronos Bio Begins Enrollment in Phase III Trial of Entospletinib in NPM1-Mutated AML
The company may seek accelerated approval of its SYK inhibitor with chemo based on results from the AGILITY trial, which are expected in 2023.
FDA Approves Genentech's Rituxan, Chemo for CD20-Positive Pediatric Leukemia, Lymphoma Patients
The agency approved the agent based on the Phase III Inter-B-NHL Ritux 2010 trial, which discontinued randomization due to positive interim data.
Nov 12, 2021
Sep 28, 2021